Andreas Jekle

Andreas Jekle is a virologist at Aligos Therapeutics focusing on the preclinical and clinical virology for their HBV capsid assembly modulator ALG-000184 and SARS-CoV-2 protease inhibitor ALG-097558. He received his PhD in cell biology in 2000 from the Eberhard-Karls University in Tϋbingen, Germany and his postdoctoral training at the J David Gladstone Institute/UCSF, focusing on HIV pathogenesis. Since 2003, he worked on antiviral drug discovery (HIV, Dengue, HCV, Influenza, RSV, Rhinovirus, HBV and SARS-CoV-2) at Roche Palo Alto, Novabay Pharma, Alios Biopharma, and since 2018 Aligos Therapeutics.